Metabolic Disorders Drugs Global Market Report 2018

Metabolic Disorder Drugs Global Market Report 2018 Including: Anti-diabetic drugs; Anti-thyroid drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism) Covering: Sanofi S.A, Novo Nordisk A/S, AstraZeneca Plc, Johnson & Johnson, Merck & Co

Feb 2018

Reasons to Purchase • Outperform competitors using accurate up to date demand-side dynamics information.

• Identify growth segments for investment.

• Facilitate decision making on the basis of historic and forecast data and the drivers and restraints on the market.

• Create regional and country strategies on the basis of local data and analysis.

• Stay abreast of the latest customer and market research findings • Benchmark performance against key competitors.

• Develop strategies based on likely future developments.

• Utilize the relationships between key data sets for superior strategizing.

• Suitable for supporting your internal and external presentations with reliable high quality data and analysis • Gain a global perspective on the development of the market.

• Report will be updated with the latest data and delivered to you within 3-5 working days of order.

Scope Markets Covered: Anti-diabetic drugs; Anti-thyroid drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism) Companies Mentioned: Sanofi S.A, Novo Nordisk A/S, AstraZeneca Plc, Johnson & Johnson, Merck & Co Countries: Brazil, China, France, Germany, India, Italy, Japan, Spain, Russia, UK, USA and Australia.

Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East And Africa Time series: Five years historic and forecast.

Data: Ratios of market size and growth to related markets, GDP, Expenditure Per Capita, Metabolic Disorder Drugs Market Indicators Comparison.

Data segmentations: Country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Metabolic Disorder Drugs Market Characteristics The metabolic disorders drugs market covers medications that are used in the treatment of metabolic diseases such as diabetes, thyroid, hyperparathyroidism, hypopituitarism, and hypoadrenalism. Some of the major drugs used in the treatment of metabolic diseases are Insulin, Methimazole, and Calcimimetics. The market numbers within this briefing are restricted to pharmaceutical (drug) treatments and do not cover biologic treatments for these conditions which are included in a separate briefing.

The metabolic disorders drugs industry is further classified as follows – Anti-Diabetic drugs companies produce drugs that can be used to manage diabetes by stabilizing and controlling blood glucose levels in diabetic patients.

Some of the major anti-diabetic drugs include Insulin, Pramlintide (Amylin), GLP-1 receptor agonists (such as Byetta and Victoza), and Oral hypoglycemics (tablets).

Anti-Thyroid Drugs companies produce drugs that can be used for treatment of an overactive thyroid (hyperthyroidism) caused by Graves' disease. These drugs are also called thionamides and some of its major examples include Methimazole and Propylthiouracil.

Other (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism) Drugs companies produce drugs for the treatment of disorders related to parathyroid glands, pituitary glands, and adrenal glands. Some of the major examples of hyperparathyroidism, hypopituitarism, hypoadrenalism drugs include Calcimimetics and Corticosteroids.

Pharmaceutical companies manufacturing metabolic disorders drugs initially involve in drug discovery process by

Metabolic Disorder Drugs Market Historic Growth The global metabolic disorder drugs market grew from $X billion in 2013 to $X billion in 2017 at a compound annual growth rate (CAGR) of X%.

The chart and table below shows the year-on-year growth of the global metabolic disorder drugs market during 2013 – 2017.

Drivers of the Market:

Restraints on the Market:

Metabolic Disorder Drugs Market Forecast Growth The global metabolic disorder drugs market is expected to grow from $X billion in 2017 to $X billion in 2021 at a compound annual growth rate (CAGR) of X%.

The chart and table below shows the year-on-year growth of the global metabolic disorder drugs market during 2017 - 2021.

Drivers of the Market:

Restraints on the Market:

Metabolic Disorder Drugs Market Segmentation The chart and table below shows the split of the metabolic disorder drugs market in 2017.

The total market value for metabolic disorder drugs was $X billion in 2017. The markets that are covered include Anti-diabetic drugs; Anti-thyroid drugs; Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism) Anti-diabetic drugs market was the x largest segment in the metabolic disorder drugs market with X% share of the market. The market value for the Anti-diabetic drugs market was $x billion in 2017.

Anti-thyroid drugs made up around X% share of the market. The market value for the anti-thyroid drugs was $x billion in 2017.

Metabolic Disorder Drugs Market Regional And Country Analysis The Asia Pacific was the x largest region in the metabolic disorder drugs market in 2017, metabolic disorder drugs for $X billion or X% market share.

North America was the x largest region in the metabolic disorder drugs accounting for $X billion or X% market share.

Europe was the x largest region in the metabolic disorder drugs accounting for $X billion or X% market share.

Metabolic Disorder Drugs Market Competitive Landscape The leading competitors in the global metabolic disorder drugs market are Sanofi S.A, Novo Nordisk A/S, AstraZeneca Plc, Johnson & Johnson, Merck & Co. The chart and table below displays the percentage market share of the top players in the metabolic disorder drugs market industry.

Company Profile Sanofi S.A Overview Products and Services Strategy Financial Performance

Novo Nordisk A/S Overview Products and Services Strategy Financial Performance

AstraZeneca Plc Overview Products and Services Strategy Financial Performance

Johnson & Johnson Overview Products and Services Strategy Financial Performance

Merck & Co. Overview Products and Services Strategy Financial Performance